Compassionate Certification Centers to Expand and Implement CBD Clinical Studies in Pennsylvania
Headquartered in Pittsburgh, physician-owned Compassionate Certification Centers currently has seven medical cannabis certification offices throughout western Pennsylvania, with another seven locations coming soon.
Once opened, the expanded medical marijuana health network will officially have clinics located in Allegheny, Armstrong, Butler, Cumberland County, Clarion, Dauphin, Erie, Westmoreland, Washington, Greene, Philadelphia, Lackawanna, and West Chester counties.
At these clinics, Compassionate Certification Centers provides patient evaluations and continued treatment services for patients in addition to offering its own line of THC-free CBD products, available to both patients and non-cardholders.
Now, in an effort to further expand the research surrounding medicinal benefits of marijuana, Compassionate Certification Centers recently announced a strategic partnership with Affinity Bio Partners, a Clinical Research Organization, to implement clinical studies on medical marijuana, hemp, and cannabinoids.
Affinity Bio Partners is a women-owned CRO that provides best-in-class services while maintaining a personal approach. They were selected as a partner for this research because of their high standards for attention, services and results.
“We are very excited for this opportunity to combine the resources of Compassionate Certification Centers and Affinity Bio Partners in order to further expand medical cannabis research. Partnerships such as these will provide the platform to increased research, better patient care, and integration of medical cannabis into our healthcare system, stated Dr. Bryan Doner, Compassionate Certification Centers co-founder and Chief Medical Officer.
“Compassionate Certification Centers’ focus on research and vision for a more inclusive healthcare system aligns with our own,” stated Christina DiArcangelo Puller, CEO, Affinity Bio Partners. “Together, we will help meet patient needs and pioneer clinical research in lieu of medical cannabis, CBD, and hemp studies. Our work will aid in the validity of the cannabis plant as an alternative therapeutic treatment.”